The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
gai zuo kang ji an lv di ping
Author(s): 
Pages: 248
Year: Issue:  4
Journal: World Clinical Drugs

Keyword:  钙拮抗剂持续性心绞痛持续心绞痛艹卓地尔硫纳多洛尔变异型β-阻滞剂双盲试验心纹痛;
Abstract: <正> 氨氯地平(amlodipine besylate)为双氢吡啶钙拮抗剂,已由美国FDA批准经口服每日1次治疗高血压、慢性持续性心绞痛及血管痉挛(变异型)性心绞痛。药动学氨氯地平从胃肠道缓慢吸收;1次口服后6~12小时可达血药峰值,并可达到1周的稳定状态。此药在肝内代谢,并随尿排出,其半减期为30~50小时。老年患者代谢较慢,血药峰值较高。临床评价对慢性持续性心绞痛患者所作的双盲试验发现,氨氯地平较安慰剂有效,在减少心绞痛发作次数和增加运动时间方面与地尔硫(艹卓)或β-阻滞剂纳多洛尔(nadolol)一样有效。134例慢性持续心绞痛患者在单
Related Articles
No related articles found